Llisterri J.L.,Primary Care Center Ingeniero Joaquin Benlloch |
Rodriguez-Roca G.C.,Primary Care Center La Puebla Of Montalba N |
Escobar C.,Hospital Universitario La Paz |
Alonso-Moreno F.J.,Primary Care Center Silleria |
And 6 more authors.
Journal of Hypertension | Year: 2012
Objectives: To examine the evolution of hypertension management and blood pressure (BP) control in Spain in the last decade across PRESCAP 2002, 2006 and 2010. Methods: The methodology of the three studies was the same. They were multicenter and cross-sectional surveys aimed to determine BP control rates in hypertensive patients in primary care in Spain during 2002, 2006 and 2010, respectively. In each study, patients at least 18 years, with an established diagnosis of hypertension were included. Adequate BP control was defined as BP less than 140/90 mmHg in the general population (<130/85 mmHg in PRESCAP 2002 and less than 130/80 mmHg in PRESCAP 2006 and PRESCAP 2010 for patients with diabetes, chronic kidney disease and cardiovascular disease). Results: A total of 12 754 patients (mean age 63.3 ± 10.8 years; 57.2% women), 10 520 patients (64.6 ± 11.3 years; 53.7% women) and 12 961 patients (66.3 ± 11.4; 52.0% women) were included in PRESCAP 2002, PRESCAP 2006 and PRESCAP 2010 studies respectively. With regard to BP control rates, 36.1% [95% confidence interval (CI) 35.2-36.9%], 41.4% (95% CI 40.5-42.4%) and 46.3% of patients (95% CI 45.4-47.1%) achieved BP goals in PRESCAP 2002, PRESCAP 2006 and PRESCAP 2010, respectively (P < 0.0001). In PRESCAP 2002, 56% of patients were on monotherapy, 35.6% were taking two drugs and 8.4% at least three drugs. In PRESCAP 2006 these numbers were 44.4, 41.1 and 14.5%, respectively, and in PRESCAP 2010 they were 36.4, 44.1 and 19.5%, respectively (P < 0.0001). Conclusion: BP control rates have improved in Spain from 2002 to 2010. This may be related, at least in part, with the higher use of antihypertensive treatment, particularly combined therapy. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source
Coca A.,University of Barcelona |
Mazon P.,Hospital Clinico Universitario |
Aranda P.,Hospital General Universitario Carlos Haya |
Redon J.,Hospital Clinico Universitario |
And 7 more authors.
Expert Review of Cardiovascular Therapy | Year: 2013
Dihydropyridinic calcium channel blockers are a subclass of antihypertensive drugs with growing significance in the therapeutic armamentarium. Early studies in the 1990s had aroused certain fears with regard to the safety of the first drugs from this class, since they had a fast onset of action and a short half-life, and thus they were associated with reflex adrenergic activation. New molecules with long half-lives and high lipophilia have shown safety and efficacy in the control of blood pressure, as well as in the reduction of several end points related to hypertension. Moreover, these new molecules, which block special subtypes of calcium channel receptors, provide drugs not only with an action profile that goes beyond the antihypertensive effect, but also with a lower rate of side effects. Therefore, in the light of new studies that include calcium channel blockers alone or in combination, these agents will probably be used even more extensively for the management of hypertension in the following years. © 2013 Expert Reviews Ltd. Source
Simarro M.,Primary Care Center Zone |
Carbayo J.A.,Medical Corps |
Carbayo J.A.,University Miguel Hernandez |
Artigao L.M.,University Miguel Hernandez |
And 8 more authors.
Experimental and Clinical Cardiology | Year: 2014
Fibrinogen is present in every stage of the atherosclerosis process. The objective of this study is to assess the association of fibrinogen with both cardiovascular mortality and all-cause mortality in a general population sample obtained by random sampling in the Spanish province of Albacete, in southern Europe. A total of 1,231 individuals who had been followed up for an average of 10.6 years (SD=2.3) volunteered to participate in a prospective cohort study. The use of fibrinogen as a predictor variable has been assessed applying the Cox regression model after adjusting fibrinogen levels for sex, age, hypertension, diabetes mellitus, obesity, total cholesterol, HDLcholesterol/ triglycerides ratio, smoking habit, and history of previous cardiovascular diseases. The mean age of the participants (674, i.e. 54.8% of them women) was 48.5 years old (DE=17.9). After adjustment, each increase of 100 mg/dl of fibrinogen level yielded a hazard ratio (HR) of 1.49 (95% CI: 1.11-2.22, p=0.016) for cardiovascular mortality and a HR of 1.49 (95% CI: 1.11-1.82, p=0.002) for allcause mortality. Within the population of our study, fibrinogen is an independent predictor of cardiovascular mortality and all-cause mortality. Source